Drug Profile
Irinotecan - Yakult Honsha
Alternative Names: Campotesin; Campto; Camptosar; CPT-11; DQ 2805; HCl-Irinotecan; IHL-305; Irinotecan hydrochloride; Irinotecan liposome injection; Irinotecan semi-solid matrix; Irinotecan SSM; Irkan; Irnocam; SN 38B11; Topotecin; U 101440ELatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Yakult Honsha
- Developer Daiichi Sankyo Company; Pfizer; Sanofi; Yakult Honsha
- Class Alkaloids; Antineoplastics; Camptothecins; Carboxylic acids; Esters; Indolizines; Piperidines; Pyrans; Quinolines; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Breast cancer; Cervical cancer; Colorectal cancer; Gastrointestinal cancer; Leukaemia; Lung cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Skin cancer; Small cell lung cancer; Solid tumours; Uterine cancer
- No development reported Gastric cancer
- Discontinued Malignant-mesothelioma
Most Recent Events
- 31 Mar 2021 No development reported - Phase-II for Gastric cancer (Combination therapy, First-line therapy, Metastatic disease) in Canada (IV)
- 01 Mar 2021 Clovis Oncology in collaboration with University of California completes a phase I trial Solid tumours (Combination therapy, Late-stage disease) in USA (PO) (NCT03318445)
- 26 Feb 2021 Daiichi Sankyo Company plans to transfer rights of Topotecin to Alfresa Pharma by December 2021